ABT-199: taking dead aim at BCL-2.

Article Details

Citation

Copy to clipboard

Davids MS, Letai A

ABT-199: taking dead aim at BCL-2.

Cancer Cell. 2013 Feb 11;23(2):139-41. doi: 10.1016/j.ccr.2013.01.018.

PubMed ID

23410971 [ View in PubMed

]

Abstract

ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Venetoclax	Apoptosis regulator Bcl-2	Protein	Humans	Yes	Antagonist Inhibitor	Details